Jonathan Sheldon - Qiagen NV President

QGEN Stock  USD 42.98  0.30  0.70%   

President

Dr. Jonathan Sheldon has served as Senior Vice President Bioinformatics Business Area, Member of the Executive Committee of Qiagen N.V. since 2018. Joined QIAGEN in 2018 as Senior Vice President, Bioinformatics Business Area. He leads QIAGEN growing presence in bioinformatics, enabling customers to transform raw data from biological samples into valuable molecular insights since 2018.
Age 52
Tenure 6 years
Address Hulsterweg 82, Venlo, Netherlands, 5912 PL
Phone31 77 355 6600
Webhttps://www.qiagen.com
Sheldon came to QIAGEN from Oracle, where he was Global Vice President leading Oracle Healthcare business globally in the Health Sciences Global Business Unit and served on the executive committee. Previously, he established the bioinformatics group and served as Head of Bioinformatics at Roche Pharmaceuticals, as well as providing leadership in software firms serving the life science and healthcare sectors. He serves on the Board of Directors of the Drug Information Association . He received his B.Sc. in Biochemistry and Molecular Biology from the University of Manchester, and his Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge.

Qiagen NV Management Efficiency

The company has return on total asset (ROA) of 0.0456 % which means that it generated a profit of $0.0456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0941 %, meaning that it created $0.0941 on every $100 dollars invested by stockholders. Qiagen NV's management efficiency ratios could be used to measure how well Qiagen NV manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Qiagen NV's Return On Capital Employed is very stable compared to the past year. As of the 4th of May 2024, Return On Assets is likely to grow to 0.06, while Return On Tangible Assets are likely to drop 0.09. At this time, Qiagen NV's Other Current Assets are very stable compared to the past year. As of the 4th of May 2024, Total Current Assets is likely to grow to about 2.3 B, while Total Assets are likely to drop about 3.2 B.
The company currently holds 1.61 B in liabilities with Debt to Equity (D/E) ratio of 0.69, which is about average as compared to similar companies. Qiagen NV has a current ratio of 1.8, which is within standard range for the sector. Debt can assist Qiagen NV until it has trouble settling it off, either with new capital or with free cash flow. So, Qiagen NV's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Qiagen NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Qiagen to invest in growth at high rates of return. When we think about Qiagen NV's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Daniel RaskasDanaher
54
Jacquie RossIllumina
N/A
Michael BoxerThermo Fisher Scientific
58
Peter HornstraThermo Fisher Scientific
59
Joakim WeidemanisDanaher
55
Brian EllisDanaher
57
Mark OeneIllumina
45
Elizabeth RaeWaters
60
Tristan OrpinIllumina
49
Matthew McGrewDanaher
52
Michael TangAgilent Technologies
50
Michel LagardeThermo Fisher Scientific
49
James DitkoffDanaher
67
Stephen WilliamsonThermo Fisher Scientific
57
Angela LalorDanaher
59
John LynchWaters
N/A
Andrew ThomsonThermo Fisher Scientific
49
Henrik AncherJensenAgilent Technologies
59
Thomas LoewaldThermo Fisher Scientific
52
Mostafa RonaghiIllumina
49
Paul BianchiIllumina
53
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen NV operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 6200 people. Qiagen NV (QGEN) is traded on New York Stock Exchange in USA. It is located in Hulsterweg 82, Venlo, Netherlands, 5912 PL and employs 5,900 people. Qiagen NV is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Qiagen NV Leadership Team

Elected by the shareholders, the Qiagen NV's board of directors comprises two types of representatives: Qiagen NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Qiagen. The board's role is to monitor Qiagen NV's management team and ensure that shareholders' interests are well served. Qiagen NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Qiagen NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
Annette Koch, Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee
Stephane Bancel, Independent Member of the Supervisory Board
Peer Schatz, CEO and Managing Director
JeanPascal Viola, Senior Area
Elaine Mardis, Independent Member of the Supervisory Board
Roland Sackers, Managing Director, Chief Financial Officer, Member of the Executive Committee
Stephany Foster, Senior Resources
Thomas Theuringer, Director Communications
Brad Crutchfield, Senior Vice President - Life Sciences Business Area
Antonio Santos, Senior Operations
Dietrich Hauffe, Senior Vice President - Life Sciences Business Area
Barthold Piening, Senior Vice President Head of Global Operations, Member of the Executive Committee
Laura Furmanski, Senior Vice President - Bioinformatics Business Area
Thierry Bernard, Chief Executive Officer, Managing Director, Member of the Executive Board
Toralf Haag, Independent Member of the Supervisory Board
Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
Douglas Liu, Sr. VP of Global Operations
Manuel Mendez, Senior Vice President - Global Commercial Operations
Manfred Karobath, Independent Supervisory Director
Benedikt Braunmuehl, Senior Vice President - Global Commercial Operations
Helge Lubenow, Senior Vice President - Molecular Diagnostics Business Area
John Gilardi, VP of Corporate Communications and Investor Relations
Hakan Bjorklund, Supervisory Board Director
Jonathan Sheldon, Senior Vice President Member of the Executive Committee
Mark Gladwell, Senior Vice President Global Operations, Member of the Executive Committee
Thomas Ebeling, Independent Member of the Supervisory Board
Elizabeth Tallett, Independent Member of the Supervisory Board
Thomas Neidert, Vice Treasury
Metin Colpan, Co-Founder, Supervisory Director and Chairman of Science and Technology Committee
Werner Brandt, Independent Supervisory Director
Ulrich Schriek, Senior Vice President - Corporate Business Development
Ross Levine, Independent Member of the Supervisory Board
Lawrence Rosen, Independent Chairman of the Supervisory Board

Qiagen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Qiagen NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Qiagen NV Investors Sentiment

The influence of Qiagen NV's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Qiagen. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Qiagen NV's public news can be used to forecast risks associated with an investment in Qiagen. The trend in average sentiment can be used to explain how an investor holding Qiagen can time the market purely based on public headlines and social activities around Qiagen NV. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Qiagen NV's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Qiagen NV's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Qiagen NV's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Qiagen NV.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Qiagen NV in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Qiagen NV's short interest history, or implied volatility extrapolated from Qiagen NV options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Qiagen NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Qiagen NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Qiagen NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Qiagen Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Qiagen Nv Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qiagen NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
To learn how to invest in Qiagen Stock, please use our How to Invest in Qiagen NV guide.
Note that the Qiagen NV information on this page should be used as a complementary analysis to other Qiagen NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Qiagen Stock analysis

When running Qiagen NV's price analysis, check to measure Qiagen NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Qiagen NV is operating at the current time. Most of Qiagen NV's value examination focuses on studying past and present price action to predict the probability of Qiagen NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Qiagen NV's price. Additionally, you may evaluate how the addition of Qiagen NV to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Qiagen NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qiagen NV. If investors know Qiagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qiagen NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.07)
Earnings Share
1.52
Revenue Per Share
8.732
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0456
The market value of Qiagen NV is measured differently than its book value, which is the value of Qiagen that is recorded on the company's balance sheet. Investors also form their own opinion of Qiagen NV's value that differs from its market value or its book value, called intrinsic value, which is Qiagen NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qiagen NV's market value can be influenced by many factors that don't directly affect Qiagen NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qiagen NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Qiagen NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qiagen NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.